VERAXA Biotech AG (NASDAQ: VRXA) announced a collaboration with Ardigen S.A., a bioinformatics company specializing in artificial intelligence, to advance the development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates (ADCs). The partnership will initially focus on creating AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA's BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.
According to VERAXA, integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates.
"This partnership represents a significant step forward in our mission to develop next-generation antibody-based therapeutics," said a VERAXA spokesperson. "By combining Ardigen's AI expertise with our proprietary BiTAC platform, we aim to accelerate the identification of optimal dual-target combinations that can maximize therapeutic impact while minimizing side effects."
VERAXA's BiTAC platform is a bispecific T-cell engager technology designed to recruit immune cells to tumors more effectively. The platform has the potential to address limitations of current T-cell engagers, such as on-target off-tumor toxicity, by fine-tuning target selection. The collaboration with Ardigen will leverage machine learning algorithms to analyze complex biological data, potentially uncovering novel target pairs that are synergistic and less toxic.
For more details on the announcement, visit https://ibn.fm/GLFg2.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL) and is building a pipeline of ADCs and proprietary BiTAC formats. The company is committed to rigorous quality-by-design principles. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
Investors can find the latest news and updates on VERAXA at http://ibn.fm/VRXA.
